Noninvasive Blood Monitor Reduces Transfusions During Surgery
By LabMedica International staff writers Posted on 04 Nov 2010 |
A noninvasive continuous blood monitor that measures hemoglobin (Hb) could reduce the number of blood transfusions that are given during surgery.
A device that that continuously monitors and measures Hb in patients undergoing surgery does not require a blood sample from the patient. Current methods rely on observation and laboratory tests, which can only be done intermittently, and can take 15 - 45 minutes to get the results back to the surgical team.
In a clinical trial carried out at the Vanderbilt University Medical Center, (Nashville, TN, USA), 327 elective orthopedic surgery patients scheduled for procedures such as hip replacement (31% of patients), knee replacement (29%), and spinal surgery (14%) were randomly assigned to groups. One group of 157 patients received standard care alone during their surgery where observation and laboratory tests were used to monitor hemoglobin levels. The other group of 150 patients received standard care plus monitoring the hemoglobin levels with the device (SpHb). SpHb monitoring counts surgical patients' red blood cell levels continuously in real time, without delays and it also does it without puncturing the skin.
The blood monitor used was the Radical-7 Pulse CO-Oximeter with a R1-25 Rainbow Adhesive Sensor, Revision E, manufactured by Masimo, (Irvine, CA, USA). The device measures hemoglobin levels using near infrared light of several different wavelengths to assess the relative quantity of circulating red blood cells. The frequency of transfusions was compared during operations and the mean number of blood units transfused, in the two groups, and they also compared the frequency of laboratory Hb testing and agreement between the SpHb counts and the laboratory Hb counts. More patients received blood transfusions and the mean number of units of blood used in the transfusions was significantly higher in the standard care group than the SpHb group during their operations. The values of Hb obtained by SpHb and standard laboratory tests showed good agreement.
Jesse Ehrenfeld, M.D., the lead author of the study, noted that because the standard Hb test took so long, surgeons in the absence of timely results often go for the safest option, contributing to the 1.9 million transfusions given during surgery every year in the US. He added, "The next stage will be to do a larger trial to see how the device affects transfusion rates in other groups of patients, including those undergoing trauma and cardiac surgery, where more blood is often needed.” A report of the trial was made on October 18, 2010, at the annual meeting of the American Society of Anesthesiologists, held in San Diego, CA, USA.
Related Links:
Vanderbilt University Medical Center
Masimo
A device that that continuously monitors and measures Hb in patients undergoing surgery does not require a blood sample from the patient. Current methods rely on observation and laboratory tests, which can only be done intermittently, and can take 15 - 45 minutes to get the results back to the surgical team.
In a clinical trial carried out at the Vanderbilt University Medical Center, (Nashville, TN, USA), 327 elective orthopedic surgery patients scheduled for procedures such as hip replacement (31% of patients), knee replacement (29%), and spinal surgery (14%) were randomly assigned to groups. One group of 157 patients received standard care alone during their surgery where observation and laboratory tests were used to monitor hemoglobin levels. The other group of 150 patients received standard care plus monitoring the hemoglobin levels with the device (SpHb). SpHb monitoring counts surgical patients' red blood cell levels continuously in real time, without delays and it also does it without puncturing the skin.
The blood monitor used was the Radical-7 Pulse CO-Oximeter with a R1-25 Rainbow Adhesive Sensor, Revision E, manufactured by Masimo, (Irvine, CA, USA). The device measures hemoglobin levels using near infrared light of several different wavelengths to assess the relative quantity of circulating red blood cells. The frequency of transfusions was compared during operations and the mean number of blood units transfused, in the two groups, and they also compared the frequency of laboratory Hb testing and agreement between the SpHb counts and the laboratory Hb counts. More patients received blood transfusions and the mean number of units of blood used in the transfusions was significantly higher in the standard care group than the SpHb group during their operations. The values of Hb obtained by SpHb and standard laboratory tests showed good agreement.
Jesse Ehrenfeld, M.D., the lead author of the study, noted that because the standard Hb test took so long, surgeons in the absence of timely results often go for the safest option, contributing to the 1.9 million transfusions given during surgery every year in the US. He added, "The next stage will be to do a larger trial to see how the device affects transfusion rates in other groups of patients, including those undergoing trauma and cardiac surgery, where more blood is often needed.” A report of the trial was made on October 18, 2010, at the annual meeting of the American Society of Anesthesiologists, held in San Diego, CA, USA.
Related Links:
Vanderbilt University Medical Center
Masimo
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Cheap Cell-Free DNA Based Test Accurately Predicts Preterm Birth
Preterm birth (PTB) occurs in around 11% of all births globally, leading to considerable morbidity and mortality for both mothers and their newborns. Identifying pregnancies at risk of PTB early in gestation... Read more
RNA Blood Test Detects Cancers and Resistance to Treatment
A newly developed blood test offers the ability to detect cancer, understand how cancer resists treatments, and assess tissue damage from non-cancerous conditions. This innovative test, created by researchers... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read more
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more